1. Home
  2. WOOF vs SGMT Comparison

WOOF vs SGMT Comparison

Compare WOOF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Petco Health and Wellness Company Inc.

WOOF

Petco Health and Wellness Company Inc.

N/A

Current Price

$2.45

Market Cap

713.2M

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

N/A

Current Price

$9.08

Market Cap

761.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WOOF
SGMT
Founded
1965
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
713.2M
761.6M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
WOOF
SGMT
Price
$2.45
$9.08
Analyst Decision
Hold
Buy
Analyst Count
12
12
Target Price
$3.47
★ $27.27
AVG Volume (30 Days)
★ 3.6M
899.0K
Earning Date
12-08-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 108.11
N/A
EPS
★ 0.08
N/A
Revenue
★ $5,961,467,000.00
$2,000,000.00
Revenue This Year
$0.46
N/A
Revenue Next Year
$1.23
N/A
P/E Ratio
$30.88
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.14
$4.50
52 Week High
$3.78
$11.45

Technical Indicators

Market Signals
Indicator
WOOF
SGMT
Relative Strength Index (RSI) 40.01 42.05
Support Level $2.21 $8.70
Resistance Level $2.51 $9.26
Average True Range (ATR) 0.17 0.69
MACD -0.06 -0.14
Stochastic Oscillator 2.76 8.36

Price Performance

Historical Comparison
WOOF
SGMT

About WOOF Petco Health and Wellness Company Inc.

Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: